RESUMEN

As more women at increased risk for tuberculosis (TB) reactivation immigrate to the United States, perinatal screening and chemoprophylaxis are increasingly important. Interferon-gamma release assays and the tuberculin skin test are acceptable screening tests with the latter supported by more data in pregnancy. Women screening positive should have active TB excluded, and if negative, latent TB is likely. Prophylaxis should be deferred until 3 months postpartum except in those severely immunosuppressed, human immunodeficiency virus positive, or recently exposed. Isoniazid with pyridoxine for 9 months is preferred with reasonable safety in pregnancy and breastfeeding. Monitoring for maternal hepatotoxicity is recommended.

Asunto(s)

Profilaxis Antibiótica/métodos , Antituberculosos/administración & dosificación , Complicaciones Infecciosas del Embarazo/prevención & control , Diagnóstico Prenatal/métodos , Tuberculosis/prevención & control , Adulto , Quimioterapia Combinada , Femenino , Humanos , Ensayos de Liberación de Interferón gamma , Isoniazida/administración & dosificación , Embarazo , Complicaciones Infecciosas del Embarazo/diagnóstico , Complicaciones Infecciosas del Embarazo/microbiología , Piridoxina/administración & dosificación , Prueba de Tuberculina , Tuberculosis/diagnóstico , Tuberculosis/microbiología